These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1689892)

  • 1. The side effects of FK 506 in humans.
    Shapiro R; Fung JJ; Jain AB; Parks P; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):35-6. PubMed ID: 1689892
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathologic observations in human allograft recipients treated with FK 506.
    Demetris AJ; Fung JJ; Todo S; Banner B; Zerbe T; Sysyn G; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):25-34. PubMed ID: 1689891
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.
    Venkataramanan R; Jain A; Warty VW; Abu-Elmagd K; Furakawa H; Imventarza O; Fung J; Todo S; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):931-3. PubMed ID: 1703355
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations.
    Jain AB; Venkataramanan R; Cadoff E; Fung JJ; Todo S; Krajack A; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):57-9. PubMed ID: 1689900
    [No Abstract]   [Full Text] [Related]  

  • 5. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates.
    Monden M; Gotoh M; Kanai T; Valdivia LA; Umeshita K; Endoh W; Nakano Y; Kawai M; Ohzato H; Ukei T
    Transplant Proc; 1990 Feb; 22(1):66-71. PubMed ID: 1689904
    [No Abstract]   [Full Text] [Related]  

  • 6. Lymphoproliferative disorders after FK 506.
    Kitahara S; Makuuchi M; Kawasaki S; Ishizone S; Matsunami H; Kamada N; Kawarazaki H; Iwanaka T
    Lancet; 1991 May; 337(8751):1234. PubMed ID: 1708846
    [No Abstract]   [Full Text] [Related]  

  • 7. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation.
    Van Thiel DH; Iqbal M; Jain A; Fung J; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):37-40. PubMed ID: 1689893
    [No Abstract]   [Full Text] [Related]  

  • 8. Transplantation's newest weapon FK 506.
    Pezze JL; Whiteman K
    Am J Nurs; 1991 Oct; 91(10):40-2. PubMed ID: 1716857
    [No Abstract]   [Full Text] [Related]  

  • 9. The question of FK 506 nephrotoxicity after liver transplantation.
    McCauley J; Takaya S; Fung J; Tzakis A; Abu-Elmagd K; Jain A; Todo S; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1444-7. PubMed ID: 1703344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infections in adult liver transplant patients under FK 506 immunosuppression.
    Alessiani M; Kusne S; Martin M; Jain A; Abu-Elmagd K; Moser J; Todo S; Fung J; Starzl T
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1501-3. PubMed ID: 1703345
    [No Abstract]   [Full Text] [Related]  

  • 11. Altered bioavailability of tacrolimus following intravenous administration of tigecycline.
    Pavan M; Chaudhari AP; Ranganth R
    Am J Kidney Dis; 2011 Feb; 57(2):354. PubMed ID: 21251548
    [No Abstract]   [Full Text] [Related]  

  • 12. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study.
    Tiebosch A; Ericzon BG; Wijnen R; Arends JW; Groth CG; Kootstra G
    Transplant Proc; 1990 Aug; 22(4):1652. PubMed ID: 1697115
    [No Abstract]   [Full Text] [Related]  

  • 13. Serious interaction between tacrolimus FK506 and chloramphenicol in a kidney-pancreas transplant recipient.
    Bakri R; Breen C; Maclean D; Taylor J; Goldsmith D
    Transpl Int; 2003 Jun; 16(6):441-3. PubMed ID: 12819878
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation.
    Kang Y; Mazer MA; DeWolf AM; Fung JJ; Gasior T; Venkataramanan R; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):21-2. PubMed ID: 1689889
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction of graft acceptance after dog kidney or liver transplantation.
    Ueda Y; Todo S; Eiras G; Furukawa H; Imventarza O; Wu YM; Oks A; Zeevi A; Oguma S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):80-2. PubMed ID: 1689909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of FK 506 in pediatric patients.
    Tzakis AG; Fung JJ; Todo S; Reyes J; Green M; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):924-7. PubMed ID: 1703353
    [No Abstract]   [Full Text] [Related]  

  • 17. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population.
    Nalesnik MA; Demetris AJ; Fung JJ; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1108-10. PubMed ID: 1703335
    [No Abstract]   [Full Text] [Related]  

  • 18. FK 506--an investigational immunosuppressant.
    Med Lett Drugs Ther; 1991 Oct; 33(854):94. PubMed ID: 1716722
    [No Abstract]   [Full Text] [Related]  

  • 19. Pancreaticoduodenal allotransplantation with FK 506 in the dog.
    Morimoto T; Yamada F; Kobayashi T; Miyaishi S; Tokumaru T; Kamiya I; Takagi H
    Transplant Proc; 1990 Apr; 22(2):717-9. PubMed ID: 1691550
    [No Abstract]   [Full Text] [Related]  

  • 20. Toxicologic evaluation of FK 506.
    Ohara K; Billington R; James RW; Dean GA; Nishiyama M; Noguchi H
    Transplant Proc; 1990 Feb; 22(1):83-6. PubMed ID: 1689910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.